{rfName}
Sa

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Mostaza JmCorresponding Author

Share

December 26, 2022
Publications
>
Article

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial

Publicated to: Bmc Cardiovascular Disorders. 22 (1): 560- - 2022-12-22 22(1), DOI: 10.1186/s12872-022-03013-w

Authors:

Mostaza, Jose M; Suarez-Fernandez, Carmen; Cosin-Sales, Juan; Gomez-Huelgas, Ricardo; Brotons, Carlos; Pestana Araujo, Francisco; Borrayo, Gabriela; Ruiz, Emilio
[+]

Affiliations

Biomed Res Inst Sant Pau, Barcelona, Spain - Author
Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), Malaga, Spain. - Author
Biomedical Research Institute Sant Pau, Barcelona, Spain. - Author
Cardiology Service, Hospital Arnau de Vilanova, Valencia, Spain. - Author
Corporate Medical Affairs Department, Ferrer Internacional, Barcelona, Spain. - Author
Fdn Invest Biomed Hosp Princesa, Madrid, Spain - Author
Ferrer Int, Corp Med Affairs Dept, Barcelona, Spain - Author
Fundación Investigación Biomédica del Hospital de la Princesa, Madrid, Spain. - Author
Hosp Arnau Vilanova, Cardiol Serv, Valencia, Spain - Author
Hosp Carlos III, Internal Med Serv, Madrid, Spain - Author
Hosp Lusiadas, Lisbon, Portugal - Author
Hosp Princesa, Internal Med Dept, Madrid, Spain - Author
Hospital dos Lusíadas, Lisbon, Portugal. - Author
Inst Mexicano Seguro Social IMSS, Mexico City, Mexico - Author
Instituto Mexicano del Seguro Social (IMSS), Ciudad de Mexico, Mexico. - Author
Internal Medicine Department Hospital de la Princesa, Madrid, Spain. - Author
Internal Medicine Department, Regional University Hospital of Málaga, Malaga, Spain. - Author
Internal Medicine Service, Hospital Carlos III, Madrid, Spain. josemaria.mostaza@salud.madrid.org. - Author
Medicine Department, Facultad de Ciencias de la Salud, Universidad UCH-CEU, Alfara del Patriarca, Valencia, Spain. - Author
NULL - Author
Reg Univ Hosp Malaga, Internal Med Dept, Malaga, Spain - Author
Sardenya Primary Health Care Center, Barcelona, Spain. - Author
Sardenya Primary Hlth Care Ctr, Barcelona, Spain - Author
Univ Autonoma Madrid UAM, Madrid, Spain - Author
Univ Malaga UMA, Biomed Res Inst Malaga IBIMA, Malaga, Spain - Author
Univ UCH CEU, Fac Ciencias Salud, Med Dept, Alfara Del Patriarca, Valencia, Spain - Author
Universidad Autónoma de Madrid (UAM), Madrid, Spain. - Author
See more

Abstract

Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event.The VULCANO was an international, multicentre open-label trial involving 492 participants recruited from hospital clinics or primary care centres. Patients were randomised to the CNIC-polypill -containing aspirin, atorvastatin, and ramipril- or usual care. The primary outcome was the comparison of the mean change in LDL-c and SBP values after 16 weeks of treatment between treatment groups.The upper confidence limit of the mean change in LDL-c between treatments was below the prespecified margin (10 mg/dL) and above zero, and non-inferiority and superiority of the CNIC-polypill (p = 0.0001) was reached. There were no significant differences in SBP between groups. However, the upper confidence limit crossed the prespecified non-inferiority margin of 3 mm Hg. Significant differences favoured the CNIC-polypill in reducing total cholesterol (p = 0.0004) and non-high-density lipoprotein cholesterol levels (p = 0.0017). There were no reports of major bleeding episodes. The frequency of non-serious gastrointestinal disorders was more frequent in the CNIC-polypill arm.The switch from conventional treatment to the CNIC-polypill approach was safe and appears a reasonable strategy to control risk factors and prevent CVD. Trial registration This trial was registered in the EU Clinical Trials Register (EudraCT) the 20th February 2017 (register number 2016-004015-13; https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004015-13 ).© 2022. The Author(s).
[+]

Keywords

Antihypertensive agentsCardiovascular diseaseCardiovascular diseasesCardiovascular risk factorsCholesterolCholesterol, ldlDrug combinationsFixed-dose combinationHumansHydroxymethylglutaryl-coa reductase inhibitorsNon-inferiority trialPolypillPrimary prevention

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal BMC Cardiovascular Disorders due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Cardiology and Cardiovascular Medicine. Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Cardiac & Cardiovascular Systems.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.2. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.14 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-05, the following number of citations:

  • WoS: 10
  • Scopus: 10
  • Europe PMC: 9
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 49.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 49 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Mexico; Portugal.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (MOSTAZA PRIETO, JOSE MARIA) .

the author responsible for correspondence tasks has been MOSTAZA PRIETO, JOSE MARIA.

[+]